The main pharmacovigilance updates in 2020 are reviewed Remdesivir in COVID-19: relatively safe but turns out to be less effective than expected Hydroxychloroquine in COVID-19 : lack of efficacy and risk of arrhythmias Cytokines storm in COVID-19: may impact pharmacokinetics VEGF inhibitors: risk of aneurysm and artery dissection Tofacitinib: dose-dependant risk of venous thromboembolic events Ondansetron in the first trimester of pregnancy : a highly debated risk of orofacial cleft defects Fingolimod : contraindicated during pregnancy due to suspected risk of congenital malformations Ranitidine: global market withdrawal due to contamination with nitrosamines Ulipristal for uterine fibroids : market withdrawal due to risk of severe liver injury Ingenol mebutate : market withdrawal due to paradoxical risk of skin cancers
[Pharmacovigilance update]